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Abstract 
Human Isocitrate dehydrogenase (IDH) occurs in 
three isozymes, IDH1, located in the cytoplasm, and 
IDH2 and IDH3 located in the mitochondria. IDH 
functions as part of the tricarboxylic acid (TCA) 
cycle and catalyzes the reversible conversion of 
isocitrate to alpha ketoglutarate (α-KG)/2-
oxoglutarate (2-OG), thus promoting the activity of 
dioxygenases that require α-KG as a cosubstrate. 
IDH1 and IDH2 use NADP+ as a cofactor, 
producing NADPH in the process (NADPH plays a 
vital role in the regeneration of the antioxidant 
glutathione), whereas IDH3 uses NAD+ as a 
cofactor and produces NADH. Somatic 
heterozygous mutations in the active site of IDH1 (at 
position R132) or IDH2 (at position R140 or R172) 
have been reported in a spectrum of human tumors : 
gliomas, hematologic malignancies including 
myeloproliferative neoplasms, myelodysplastic 
syndromes and acute myeloid leukemia, and also 
angioimmunoblastic T-cell lymphoma and primary 
central nervous system lymphoma, 
cholangiocarcinoma, chondrosarcomas, and other 
malignancies. IDH mutations lead to a neomorphic 
enzymatic activity of the mutated IDH enzyme, 
resulting in the conversion of α-KG to R-2-
hydroxyglutarate (R2-HG). Supra-normal levels of 
intracellular 2-HG interfere with several α-KG-
dependent dioxygenases, notably enzymes involved 
in methylation of histones (histone lysine 
demethylases, KDMs) and DNA (TET family of 
DNA hydroxylases). 
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Identity 
Other names 
IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; 
mNADP-IDH 
HGNC (Hugo) 
IDH2 
Location 
15q26.1 
Note 
Isocitrate dehydrogenases catalyze the oxidative 
decarboxylation of isocitrate to 2-oxoglutarate. 
These enzymes belong to two distinct subclasses, 
one of which utilizes NAD(+) as the electron 
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acceptor and the other NADP(+). In human, five 
isocitrate dehydrogenases genes have been reported:  
three NAD(+)-dependent isocitrate dehydrogenases 
(IDH3A, IDH3B, IDH3G) , which localize to the 
mitochondrial matrix. IDH3 catalyzes the 
allosterically regulated rate-limiting step of the 
tricarboxylic acid cycle. IDH3 is a heterotetramer 
that is composed of two alpha subunits, one beta 
subunit, and one gamma subunit;  
and two NADP(+)-dependent isocitrate 
dehydrogenases, one of which is mitochondrial 
(IDH2) and the other ( IDH1) predominantly 
cytosolic. Each NADP(+)-dependent isozyme is a 
homodimer. IDH2 plays a role in intermediary 
metabolism and energy production and may tightly 
associate or interact with the pyruvate 
dehydrogenase complex. 
DNA/RNA 
Note 
Alternative splicing of IDH2 gene results in multiple 
transcript variants. [provided by RefSeq, Feb 2014] 
 
Genomic location of the three IDH2 isoforms on chr15q26.3 (build hg19) transcribed in the reverse strand of the 
genome (UCSC or RefSeq)
. 
Description 
The various isocitrate dehydrogenases are  
IDH1 isocitrate dehydrogenase 1 (NADP+), an 
homodimer located in 2q33.3, localized in cytoplasm 
IDH2 isocitrate dehydrogenase 2 (NADP+), 
mitochondrial, located in 15q26.1, localized in 
mitochondria 
IDH3 isocitrate dehydrogenase 3 (NAD+) 
,composed of 3 subunits (IDH3A, 15q25.1), 
(IDH3B, 20p13), and IDH3G, Xq28), localized in 
mitochondrion . 
Transcription 
The sequence of IDH2 is defined by 610 GenBank 
accessions from 560 cDNA clones, some from brain 
(seen 50 times), liver (31), prostate (22), testis (20), 
uterus (19), colon (18), stomach (17) and 141 other 
tissues (from Acembly). 
IDH2 gene has 3 transcript isoforms (RefSeq): 
 
 
 
IDH2 at chr15:90627211-90645786 - (NM_002168) 
isocitrate dehydrogenase [NADP], mitochondrial 
isoform 1 precursor (Genomic size: 18576; strand -, 
11 exons).IDH2 at chr15:90627211-90643853 
- (NM_001289910) isocitrate dehydrogenase 
[NADP], mitochondrial isoform 2 (Genomic size: 
16643; strand -, 11 exons). 
IDH2 at chr15:90627211-90645786 - 
(NM_001290114) isocitrate dehydrogenase 
[NADP], mitochondrial isoform 3 (Genomic size: 
18576; strand -, 9 exons). 
On the other hand enSembl cites 5 transcripts and 4 
phenotypes. 
Pseudogene 
In the human genome exists an IDH1 pseudogene in 
6p24, (B4DXS4_HUMAN, chr6: 7516836-
7517533) homolog of IDH2 (92%) present in 
monkeys (99.1% identity with the NM_001265779.2 
transcript in the case of Rhesus). 
Protein 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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Structure of the primary sequence of IDH2 with the main features. 
 
Description 
The 3 IDH2 isoforms have 452, 400 and 332 amino 
acids (aa) respectively and are homodimers. The 
differences are in the NH2 part. UNIPROT cites 
uniquely 2 isoforms (P48735-1, 452 aa, and P48735-
2, 400 aa) [http://www.uniprot.org/uniprot/P48735 
]. The third isoform deduced from RefSeq lacks 120 
NH2 aa. 
 3D_Structure The first 3D structure solved in 
human was the homodimer IDH1 (wild type and 
mutant R132 (UNIPROT:P75874 and PDB: 3mar, 
Yang et al, 2010). The first structure of mammalia 
IDH2 was that of Sus Scrofa (UNIPROT: P33198 
and PDB: 1wld, Ceccarelli et al, 2002). The 3D 
structure of human IDH2 (mutated as R140Q) has 
been realized as a complex with an IDH2 inhibitor 
(PDB: 4ja8, Wang et al., 2013) by replacement in 
IDH1 structure. All these structures belong to the 
superfamily c.77.1: Isocitrate/Isopropylmalate 
dehydrogenase-like, a class of alpha and beta 
proteins (a/b) and a fold consisted of two intertwined 
(sub) domains related by pseudo dyad; the 
constituent families contains a typical Rossman fold 
of dehydrogenase to adapt the binding of NAD(P)+ 
and form similar dimers with the active site between 
the two identical subunits 
(http://scop.berkeley.edu/sunid=53659). 
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Comparison of primary structures of mitochondrial (IDH2; P48735) and cytoplasmic (IDH1 ; P75874) isocitrate 
dhydrogenases (73% identity). * denote the two arginines R140 and R172. 
Expression 
The IDH2 gene is expressed at very high level, 5 
times the average gene expression. IDH2 is  
 
 
expressed particularly at higher level in heart, 
stomach, muscle, thymus, kidney. 
 
 
3D structure of the human IDH2 dimer (modelised by SwissModel from Sus Scrofa IDH2 complexed with 
Mn2+ isocitrate (PDB:1wld) (panel A). Topological secondary structure of IDH2 mutated (PDB:4ja8) (from 
PDBSum : www.ebi.ac.uk/pdbsum) (panel B) with the position of the two potential mutations (R140 and R172)
. Localisation 
Mitochondrion; Translated in the cytoplasm, IDH2 
goes to mitochondrial matrix via a specific transit 
peptide NH2 (1-45). 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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 IDH occurs in three isoforms, IDH1, located in the cytoplasm, IDH2 and IDH3, located in the 
mitochondria, which function as part of the tricarboxylic acid (TCA) cycle or "Krebs cycle" IDH 
proteins catalyze the oxidative decarboxylation of isocitrate to produce CO2 and alpha-
ketogluatarate (α-KG). The reaction requires the presence of the cofactor NADP+ as electron 
acceptor, generating nicotinamide adenine dinucleotide phosphate (NADPH). IDH1 and IDH2, are 
homodimeric enzymes. 
Function 
This protein catalyzes the oxidative decarboxylation 
of isocitrate to 2-oxoglutarate and is specific of 
NADP(+). IDH2 plays a role in intermediary 
metabolism and energy production. It may tightly 
associate or interact with the pyruvate 
dehydrogenase complex. 
Catalytic activity EC:1.1.1.42 . For the wild type 
enzyme the catalytic reaction is : 
Isocitrate + NADP(+) -> 2-oxoglutarate + CO(2) + 
NADPH. 
In mutated forms (R140 or R172), there is an 
abnormal conversion of 2-oxoglutarate to 2-
hydroxyglutarate (2-HG). 
Isocitrate + NADP(+) -> 2-hydrocyglutarate + 
CO(2) + NADPH. 
Cofactor Mg(2+); Mn(2+). 1 Mg(2+) or Mn(2+) ion 
per subunit. Required for activity. 
This second specific activity is related to the role of 
2-HG as inhibitor of enzymes implicated in 
demethylation of DNA (TET2 and other 
demethylases) (Nakajima et al. 2014, Scourzic et al, 
2015). 
Post translational modification Acetylation at Lys-
413 dramatically reduces catalytic activity. 
 
Role of IDH2 in TCA cycle and of the mutated form 
in inhibition of demethylation pathways .by 
competition of 2-HG for the α-KG on TET2 (adapted 
from Nakajima , 2014). 
Homology 
In molecular biology, the isocitrate/isopropylmalate 
dehydrogenase family is a protein family consisting 
of the evolutionary related enzymes isocitrate 
dehydrogenase, 3-isopropylmalate dehydrogenase 
and tartrate dehydrogenase. IDH is well conserved in 
eucaryota in a two separate lineages (cytoplasmic, 
IDHC or IDH1 and mitochondrial, IDHP or 
IDH2)(AI et al, 2014). The mammalian NADP+-
IDH2 enzyme are structurally compared with the 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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previously solved structures of IDH from E. coli and 
Bacillus subtilis that share 16 and 17% identity, 
respectively, with the mammalian enzyme. The 
mammalian enzyme has a protein fold similar to the 
bacterial IDH structures with each monomer folding 
into two domains. However, considerable 
differences exist between the bacterial and 
mammalian forms of IDH in regions connecting core 
secondary structure. In human IDH1 and IDH2 have 
72 % identity. 
Mutations 
The COSMIC database (v75) displays 88 unique 
mutations for 38867 samples 
The main mutations of IDH2 are R140Q and R172K 
in haematopoeitic and central nervous system 
neoplasms 
 
Repartition of IDH2 mutations (in great part on aa R140 and R172) in different sites and tumors (limited to more 
or equal than 3) 
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Mutated IDH1/2 result in the conversion of alpha ketoglutarate (α-KG) to hydroxyglutarate (2-HG). 2-HG acts 
as an antagonist of α-KG. 
 
α-KG is a substrate for methyl-cytosine 
demethylation by TET family proteins (DNA 
demethylation at CpG islands) 
α-KG is a substrate for histone demethylation by 
Jumonji (JMJ) histone demethylases. 
Implicated in 
Somatic point mutations in IDH1/2 confer a gain-of-
function in cancer cells. Mutated IDH1/2 results in 
the conversion of alpha ketoglutarate to 
hydroxyglutarate (2-HG) an oncometabolite, leading 
to hypermethylation and a block in cell 
differentiation alpha-KG dependent dioxygenases 
hydroxylate various substrates and regulate many 
cellular pathways (collagen, histones, transcription 
factors, alkylated DNA and RNA, lipids).  
2-HG is structurally similar to and acts as an 
antagonist of alpha-KG.  
High levels of 2-HG lead to hypermethylation, 
resulting in epigenetic alterations of DNA and 
histone proteins and in a block in cell differentiation 
 
2-HG competitively inhibits alpha-KG dependent 
dioxygenases, including histone/DNA demethylases 
Jumonji (JMJ) family histone demethylases which 
control nearly all histone demethylation (for 
example KDM2A, KDM4A, KDM6A, KDM3B and 
KDM4C) and methylcytosine dioxygenases of the 
TET (ten-eleven translocation) family, which play a 
a key role in the process of DNA demethylation at 
CpG islands and other sites (Yen et al., 2010; Cairns 
et al., 2012; Yang et al., 2012; Lemonnier et al., 
2016; Mondesir et al., 2016; Stein et al., 2016; Ku 
and Park, 2017).  
IDH2 mutation induces DNA hypermethylation and 
inhibits mesenchymal lineage differentiation in 
correlation with high levels of 2-HG accumulation. 
IDH2 mutant cells escape contact inhibition (Lu et 
al. 2013).  
SIRT5 regulates cellular NADPH homeostasis and 
redox potential by promoting IDH2 desuccinylation 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
mitochondrial) 
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and G6PD deglutarylation to enhance cellular 
antioxidant defense SIRT5 promotes IDH2 
desuccinylation and G6PD deglutarylation to 
enhance cellular antioxidant defense (Zhou et al., 
2016). IDH2 downregulation increases NF-kB 
activation and CHUK (IkBalpha) phosphorylation 
and elevates MMP9 activation (Yi et al., 2016). 
Various malignancies 
Mutations in IDH1 (in particular c.394C>T encoding 
a R132C substitution (affecting Arg132) and 
c.395G>A encoding a R132H substitution) or IDH2 
(in particular c.516G>C encoding R172S) occur in 
80% of WHO grade II-IV glioma, 60% of 
chondrosarcoma, 40% of angioimmunoblastic T-cell 
lymphoma, 20% of acute myeloid leukaemia 
(AML), 20% of intrahepatic cholangiocarcinoma, 
12% of skin melanoma, 10% of acute lymphocytic 
leukaemia, and 5% of colorectal cancer, see below 
(Molenaar et al 2017). 
IDH1 mutations are much more frequent than IDH2 
mutations in glioma (95%), chondrosarcoma (95%) 
and cholangiocarcinoma (80%), whereas IDH2 
mutations are equally or more frequent in blood 
malignancies: chronic myeloproliferative diseases 
(MPD) 2%, myelodysplasia (MDS) 2-7%, acute 
myeloid leukemia (AML) 8-19%, 
angioimmunoblastic T-cell lymphoma 20-42%, 
versus IDH1 mutations: MPD 
International cancer programs studies demonstrated 
frequent IDH2 mutations in acute myeloid leukemia, 
glioma, cholangiocarcinoma and primary central 
nervous system lymphoma (WHO 9680/3), but also 
to a lesser extend uterine carcinosarcoma, skin 
melanoma, and rare mutations in, colorectal 
carcinoma, bladder urothelial carcinoma, head and 
neck squamous cell carcinoma, cutaneous squamous 
cell carcinoma, hepatocellular carcinoma, lung 
adenocarcinoma, pancreatic adenocarcinoma, renal 
clear cell carcinoma and renal papillary carcinoma 
(see Figure below) (cbioportal) 
IDH2 was also reported to be downregulated in 
melanoma (Park et al., 2008), colon carcinoma (Lu 
et al., 2012) and osteosarcoma (Yi et al., 2016). 
IDH2 amplification was found mainly in breast 
cancer, esophageal carcinoma, stomach 
adenocarcinoma, pancreatic adenocarcinoma, 
ovarian serous cystadenocarcinoma, uterine corpus 
carcinoma, neuroendocrine prostate cancer and 
various other cancers (see second Figure below) 
(cbioportal). 
 
Alterations in IDH2 in various cancers (from international cancer programs studies): Green: mutations; Red: 
amplification; Blue: deletion. Abbreviations: AML: acute myeloid leukemia; PCNSL: primary central nervous 
system lymphoma; UCS: uterine carcinosarcoma; CSCC: cutaneous squamous cell carcinoma; MDS: 
myelodysplasia; NEPC: neuroendocrine prostate cancer. Screenshot from http://www.cbioportal.org 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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Mutations in IDH2 in various cancers (from international cancer programs studies): Mutations (red pots) were 
found in the following: Acute myeloid leukemia, Cholangiocarcinoma, Colorectal carcinoma, Glioma, Head and 
Neck squamous cell carcinoma, Hepatocellular carcinoma, Lung adeno carcinoma, Skin melanoma, Pancreatic 
adeno carcinoma, Uterine Carcinosarcoma, Renal Clear cell carcinoma and Renal papillary carcinoma. Screenshot 
from http://www.cbioportal.org 
Glioma: Diffuse astrocytic and 
oligodendrogial tumors  and 
Neuronal and mixed neuronal-glial 
tumors 
The 2016 World Health Organization (WHO) 
classification of tumors of the central nervous 
system takes into account IDH1 or IDH2 exon 4 
mutations (in IDH1 codon 132 and IDH2 codon 172) 
as a crucial step in the characterization of gliomas.  
Mutations in IDH1 or IDH2 occur in the vast 
majority of low-grade gliomas and secondary high-
grade gliomas, and they occur early in 
gliomagenesis. The mutations drive increased 
methylation in gliomas (Cohen et al., 2013). IDH1 is 
mutated in 40% of gliomas (roughly 70% of low-
grade gliomas, 50% of grade III, and 5 to 10% of 
primary glioblastomas) in some studies, to 75% in 
other studies, and IDH2 is mutated in about 2% of 
gliomas. Most common mutations were: R132H, 
R132C, R132G, R132S, R132L in IDH1 and 
R172K, R172M, and R172W in IH2. IDH1/IDH2 
mutations are associated with genomic profile, being 
present in nearly all the 1p19q codeleted gliomas, 
and virtually absent in gliomas with EGFR 
amplification. It is a strong and independent 
predictor of survival (Rossetto et al., 2011; Yang et 
al., 2012).  
The WHO grade II diffuse astrocytomas  and WHO 
grade III anaplastic astrocytomas  are divided into 
IDH-mutant and IDH-wildtype tumors. The IDH-
mutant category is much more frequent. The 
prognostic differences between IDH-mutant WHO 
grade II diffuse astrocytomas and WHO grade III 
anaplastic astrocytomas may not be very different. 
The prognosis of patients with IDH1/2 mutations has 
been shown to be significantly better than the 
prognosis of patients with wild-type IDH1/2 in both 
grades II diffuse astrocytomas and grade III 
anaplastic astrocytoma.  
Glioblastomas  are divided in the 2016 entral 
nervous system WHO/OMS classification into IDH-
wildtype glioblastoma (90 % of cases), most 
frequently primary or de novo glioblastoma in 
patients over 55 years, and IDH-mutant glioblastoma 
(10 %), most often secondary glioblastoma with a 
history of prior lower grade diffuse glioma in 
younger patients. The prognosis of the IDH-mutant 
cases appears more favorable.  
The diagnosis of oligodendroglioma and anaplastic 
oligodendroglioma requires the demonstration of 
both an IDH gene family mutation and combined 
1p/19q loss.  
IDH mutations are absent in tumors of childhood that 
histologically resemble oligodendroglioma, and also 
in neuronal and mixed neuronal-glial tumors (Louis 
et al., 2016).  
IDH1 and IDH2 are mutually exclusive in gliomas, 
and IDH2 mutations are mutually exclusive with 
PTEN , TP53 and ATRX mutations. Patients with 
IDH2 mutations had a higher frequency of 1p/19q 
co-deletion than IDH1 mutant patients (Wang et al., 
2016). 
Chronic myeloproliferative 
syndromes 
IDH2 R140Q and IDH2 R172K mutations can occur 
in 2% of primary myelofibrosis. IDH2 mutations can 
also occur in polycythemia vera (1.5%) or essential 
thrombocythemia (<1%) (Tefferi et al., 2010). 
IDH1/2 mutations confer worse prognosis in patients 
with myelofibrosis. Primary myelofibrosis with 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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SRSF2 mutations have frequent IDH1 and IDH2 
mutations (Lasho et al., 2012). 
Myelodysplastic syndromes (MDS) 
IDH2 R140Q and IDH2 R172K mutations have been 
found in about 6% of cases of refractory anemia with 
ringed sideroblasts, refractory anemia with excess 
blasts, chronic myelomonocytic leukemia and 
secondary acute myeloid leukemia. IDH gene 
mutations did not have any impact on overall 
survival (Kosmider et al.,2010). 
Acute myeloid leukemia (AML) 
DNMT3A , IDH1, IDH2 and TET proteins play a 
key role in the process of DNA 
methylation/demethylation and mutant proteins 
impairs myeloid differentiation. IDH1/2 and TET2 
mutations in acute myeloid leukemia are mutually 
exclusive in most cases (Paschka et al., 2010; Solary 
et al., 2014).  
IDH2 mutations are more frequent than IDH1 
mutations in AML. IDH2 mutations occur in 9 to 
16% of AML cases, according to various large 
studies. IDH2 mutations are mainly R140Q 
mutations and R172K mutations. IDH1/2 mutations 
were associated with older age, lower WBC, higher 
platelets, normal karyotype, and NPM1 mutations.  
IDH1 mutated cases of myeloid leukemia (MDS and 
AML) also harbored more DNMT3A, PHF6 and 
FLT3  mutations, whereas whereas IDH2 mutated 
cases were enriched in ASXL1, SRSF2 , RUNX1, 
STAG2 mutations.  
Data on prognostic significance of IDH1/2 mutations 
in AML has been conflicting. IDH1 or IDH2 
mutations may confer sensitivity to novel therapeutic 
approaches, including the use of demethylating 
agents (Mardis et al., 2009; Abbas et al., 2010; 
Paschka et al., 2010; Haferlach et al., 2013; Im et al., 
2014; Molenaar et al., 2015). 
Angioimmunoblastic T-cell 
lymphoma 
Angioimmunoblastic T-cell lymphoma (AITL) 
(WHO 9705/3) is one of the most frequent nodal 
peripheral T-cell lymphomas.  
Mutations are almost exclusively restricted to IDH2 
R172 (Lemonnier et al., 2016).  
IDH2 was mutated (R172K, R172G, R172T, and 
R140G mutations) in about 20% of 
angioimmunoblastic T-cell lymphomas, but not in 
other peripheral B or T-cell leukemia/lymphoma 
(Hodgkin lymphoma, non-Hodgkin B-cell 
lymphoma, B-cell acute lymphoblastic lymphoma, 
T-cell acute lymphoblastic lymphoma, anaplastic 
large cell lymphoma, enteropathy type T-cell 
lymphoma, cutaneous T-cell lymphoma, 
hepatosplenic T-cell lymphoma, extranodal NK/T-
cell lymphoma). This is the second most frequent 
mutation to be identified after TET2 in 
angioimmunoblastic T-cell lymphoma. It does not 
show prognostic significance. Overall survival and 
progression-free survival were identical in patients 
with wild-type or mutant IDH2 (Cairns et al., 2012). 
Primary central nervous system 
lymphoma (PCNSL) 
Primary central nervous system lymphoma (WHO 
9680/3) is a mature B-cell neoplasm. IDH2 
mutations were identified in approximately 10% of 
PCNSL ( see above figures from cbioportal). 
Familial hematological malignancies 
Germline IDH mutations were searched for in 104 
familial cases of hematological 
malignancies/cosegregated solid tumors. IDH1 and 
IDH2 variants were found respectively in 15 % and 
3% of cases (Hamadou et al., 2016). 
Cholangiocarcinoma 
Cholangiocarcinoma is an aggressive malignancy 
with poor prognosis. Mutations in IDH1 and IDH2 
were found only in 23% of cholangiocarcinomas of 
intrahepatic origin, in none of the extrahepatic 
cholangiocarcinomas and rarely (2%) in the other 
common gastrointestinal malignancies (colorectal, 
gastroesophageal, liver, pancreatic, and small 
intestine carcinomas). IDH1 mutations are the most 
frequent (11%-24%) and IDH2 mutations are seen in 
2%-6% of the cases. The IDH1 mutation was 
R132C, R132L, or R132G, and the IDH2 mutation 
was R172W, and neither the common glioma 
mutation R132H of IDH1 nor the common AML 
mutation at codon R140 of IDH2 was found in 
cholangiocarcinomas. KRAS, TP53, NRAS, BRAF, 
AKT1 and PTEN mutations were found each in 3-
5% of intrahepatic cholangiocarcinomas (Borger et 
al., 2012; Borger et al., 2014). 
Chondrosarcoma 
17-24% of primary malignant bone tumors are 
chondrosarcoma; enchondroma is a benign precursor 
of chondrosarcoma. While most enchondromas are 
solitary, patients with Ollier's disease and Maffucci's 
syndrome (see below) demonstrate multiple 
enchondromas (Bovée 2002). 
A large retrospective study of Ollier and Maffucci 
patients was conducted. Overall incidence of 
development of chondrosarcoma was 40%. Patients 
with enchondromas located in long bones or axial 
skeleton, especially the pelvis, have an increased risk 
of developing chondrosarcoma (Verdegaal et al., 
2011).  
More than 50% of patients with chondrosarcomas 
exhibit gain-of-function mutations in IDH1 or IDH2. 
IDH mutations were associated with DNA 
hypermethylation at CpG islands enriched for genes 
implicated in stem cell maintenance/differentiation 
and lineage specification. Introduction of mutant 
IDH2 in murine mesenchymal progenitor cells 
generated undifferentiated sarcomas (Lu et al., 
2013). 
IDH2 (isocitrate dehydrogenase 2 (NADP+), 
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Enchondromas, Ollier disease and 
Maffucci syndrome 
Ollier disease and Maffucci syndrome are non-
hereditary skeletal disorders characterized by 
multiple central cartilaginous tumors 
(enchondromas) in Ollier disease, accompanied with 
soft tissue hemangiomas (spindle cell type) or, less 
commonly, lymphangiomas in Maffucci syndrome. 
Somatic heterozygous mutations in IDH1 (R132C or 
R132H substitution) or IDH2 (R172S substitution) 
were found in 87% of enchondromas and in 70% of 
spindle cell hemangiomas. About 80% subjects with 
Ollier disease or Maffucci syndrome carried IDH1 
(98%) or IDH2 (2%) mutations in their tumors 
(while mutations of PTH1R are found in a 10% of 
patients with Ollier disease). Mesenchymal tumors, 
including cartilaginous tumors, osteosarcomas and 
other bone and soft tissue tumors, were screened for 
IDH1/IDH2 mutations. Heterozygous somatic 
IDH1/IDH2 mutations were only detected in central 
and periosteal cartilaginous tumors, and were found 
in at least 56% of these. The ratio of IDH1/IDH2 
mutation was 10.6/1. No germline mutations were 
detected. No mutations were detected in peripheral 
chondrosarcomas and osteochondromas. Low level 
of mutated DNA was identified in non-neoplastic 
tissue, a finding compatible with a model in which 
IDH1 or IDH2 mutations represent early post-
zygotic occurrences in Ollier disease and Maffucci 
syndromes (Amary et al., 2011a; Amary et al., 
2011b; Pansuriya et al., 2011). 
IDH2 and TP53 mutations have been found 
correlated with gliomagenesis in a patient with 
Maffucci syndrome (Moriya et al., 2014). 
Lung cancer 
A higher risk was observed in lung cancer patient 
carriers of rs11540478 TT and CT compared with 
CC carriers (Li et al., 2017). 
Breast cancer 
Solid papillary carcinoma with reverse polarity is a 
rare breast cancer subtype. Ten of 13 (77%) solid 
papillary carcinoma with reverse polarity harbored 
hotspot mutations at R172 IDH2, of which 8 of 10 
also displayed mutations in PIK3CA or PIK3R1 
(Chiang et al., 2016). 
D-2-Hydroxyglutaric aciduria 
IDH2 mutations were found in a subset of n patients 
with D-2-hydroxyglutaric aciduria, a 
neurometabolic inherited disorder. Patients exhibit 
cardiomyopathy, epilepsy, developmental delay and 
limited life span (Kranendijk Met al., Science. 
2012). 
Parkinson's disease 
Reduced IDH2 facilitates apoptotic cell death 
induction due to elevated mitochondrial oxidative 
stress and contributes to degeneration of the 
dopaminergic neuron in the neurotoxin model of 
Parkinson's disease (Kim et al., 2016). 
Cardiovascular disease 
IDH2 functions as an antioxidant and anti-apoptotic 
protein by supplying NADPH to antioxidant 
systems. Attenuated IDH2 expression resulted in 
reactive oxygen species-mediated cell death, which 
contributes to the pathophysiology of cardiovascular 
disease and myocardial dysfunction (Ku and Park. 
2017), and mutant IDH2 causes cardiomyopathy and 
neurodegeneration in mice (Akbay,  2014). 
To be noted 
THERAPY 
Mutant-IDH1/2 enzymes inhibitors have entered 
clinical trials for patients with IDH1/2 mutations and 
represent a novel drug class for targeted therapy 
(Mondesir et al., 2016; Molenaar et al 2017; Thomas 
and Majeti. 2017; Shih et al., 2017 Stein et al., 2017; 
Yen et al., 2017).  
Enasidenib (AG-221/CC-90007), an inhibitor of 
mutant IDH2, is being explored in a phase I clinical 
trial for the treatment of AML. AG-221 suppressed 
2-HG production and induced cellular differentiation 
in AML with IDH2 mutations. In clinical trials, 
safety outcomes for all patients was assessed, a 
substantial subset of the patients with AML had 
partial remission and additional patients had a stable 
disease. Among patients with relapsed or refractory 
AML, overall response rate was 40% (Stein et al., 
2016; Stein et al., 2017). AMLs with mutations in 
TET2 or IDH2 are sensitive to epigenetic therapy 
through inhibition of DNA methyltransferase 
activity of mutant TET2 or inhibition of mutant 
IDH2 through AG-221. These inhibitors induce a 
differentiation response (Shih et al., 2017). 
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